Thirty years of innovation pays off as oligonucleotide therapeutics come to market

The recent approval of SpinrazaTM (nusinersen) marks the arrival of a new class of biological products – oligonucleotide therapeutics. A recent publication shows that the thirty year path from the initiation of research on oligonucleotides as therapeutics to the emergence of effective products followed predictable patterns of innovation, in which novel products are successfully developed only after the underlying basic research reaches a requisite level of maturity.

from Top Health News – ScienceDaily http://bit.ly/2GgOPgP
from Tumblr http://bit.ly/2DCZ0L2